EGFR and prostate cancer: In fact, in addition to the effects of NDRG1 on inhibiting oncogenic c-Src signaling through EGFR and Rac1 reported herein, it was recently reported that the metastasis suppressor, KAI1/CD82, exerts its anti-oncogenic function in prostate cancer cells by inhibiting CDCP1-mediated enhancement of c-Src activity, leading to reduced HIF-1α and VEGF expression [70].